Literature DB >> 33349063

Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers.

Sverre E Kjeldsen1,2, Krzysztof Narkiewicz3, Michel Burnier4, Suzanne Oparil5.   

Abstract

Entities:  

Year:  2020        PMID： 33349063     DOI： 10.1080/08037051.2021.1862483

Source DB:  PubMed          Journal:  Blood Press        ISSN： 0803-7051            Impact factor:   2.835


× No keyword cloud information.
  8 in total

Review 1.  Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.

Authors:  Carmine Savoia; Massimo Volpe; Reinhold Kreutz
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

Review 2.  The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review.

Authors:  Farnoosh Nozari; Nasrin Hamidizadeh
Journal:  Int J Hypertens       Date:  2022-01-21       Impact factor: 2.420

Review 3.  Hypertension and COVID-19: Current Evidence and Perspectives.

Authors:  Giovanna Gallo; Valentin Calvez; Carmine Savoia
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-02-20

4.  Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity.

Authors:  Otavio Cabral-Marques; Gilad Halpert; Lena F Schimke; Gabriela Riemekasten; Yehuda Shoenfeld; Yuri Ostrinski; Aristo Vojdani; Gabriela Crispim Baiocchi; Paula Paccielli Freire; Igor Salerno Filgueiras; Israel Zyskind; Miriam T Lattin; Florian Tran; Stefan Schreiber; Alexandre H C Marques; Desirée Rodrigues Plaça; Dennyson Leandro M Fonseca; Jens Y Humrich; Antje Müller; Lasse M Giil; Hanna Graßhoff; Anja Schumann; Alexander Hackel; Juliane Junker; Carlotta Meyer; Hans D Ochs; Yael Bublil Lavi; Carmen Scheibenbogen; Ralf Dechend; Igor Jurisica; Kai Schulze-Forster; Jonathan I Silverberg; Howard Amital; Jason Zimmerman; Harry Heidecke; Avi Z Rosenberg
Journal:  Nat Commun       Date:  2022-03-09       Impact factor: 14.919

Review 5.  Beta receptor blocker therapy for the elderly in the COVID-19 era.

Authors:  Elpidio Santillo; Monica Migale
Journal:  World J Clin Cases       Date:  2022-08-16       Impact factor: 1.534

6.  Impact of Arterial Hypertension and Use of Antihypertensive Pharmacotherapy on Mortality in Patients Hospitalized due to COVID-19: The CRACoV-HHS Study.

Authors:  Wiktoria Wojciechowska; Michał Terlecki; Marek Klocek; Agnieszka Pac; Agnieszka Olszanecka; Katarzyna Stolarz-Skrzypek; Marek Jastrzębski; Piotr Jankowski; Aleksandra Ostrowska; Tomasz Drożdż; Aleksander Prejbisz; Piotr Dobrowolski; Andrzej Januszewicz; Marcin Krzanowski; Maciej T Małecki; Tomasz Grodzicki; Reinhold Kreutz; Marek Rajzer
Journal:  Hypertension       Date:  2022-09-09       Impact factor: 9.897

7.  Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.

Authors:  Debmalya Barh; Alaa A Aljabali; Murtaza M Tambuwala; Sandeep Tiwari; Ángel Serrano-Aroca; Khalid J Alzahrani; Bruno Silva Andrade; Vasco Azevedo; Nirmal Kumar Ganguly; Kenneth Lundstrom
Journal:  Biomedicines       Date:  2021-05-17

8.  Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry.

Authors:  Fabio Angeli; Paolo Verdecchia; Antonella Balestrino; Claudio Bruschi; Piero Ceriana; Luca Chiovato; Laura Adelaide Dalla Vecchia; Francesco Fanfulla; Maria Teresa La Rovere; Francesca Perego; Simonetta Scalvini; Antonio Spanevello; Egidio Traversi; Dina Visca; Michele Vitacca; Tiziana Bachetti
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.